08.25.26 -- Accelerate Development Across Gene Therapy And Biologics

From process development to GMP manufacturing, our teams operate as one connected system to support your cell or gene therapy through every milestone.

See who we partnered with to manufacture BEAM-101, a novel base editing therapy for sickle cell disease, advancing rapid, high-quality production towards clinical trials.

Explore how digital solutions help streamline mRNA manufacturing by reducing costs, improving efficiency, and supporting sustainability by creating paperless processes for therapeutics.

Lentiviral vector therapies present distinct testing challenges. Accessing structured release testing panels ensures rigorous safety, reliable lot disposition, and regulatory compliance.

Uncover how we support complex in vivo modalities with scalable manufacturing solutions, advanced analytics, and end to end CMC expertise across viral vector and RNA LNP platforms, from early development through clinical readiness.

This webinar provides an expert overview of how we leverage advanced mammalian cell culture platforms to enable efficient, scalable biopharmaceutical development and manufacturing.

Optimized synthetic DNA enables gene and RNA therapies with improved stability, expression, and delivery, supporting advanced applications across viral, non-viral, and vaccine platforms.

Successful cell therapy programs rely on evolving, science‑driven partnerships that integrate CMC strategy, deepen rigor over time, and translate complex research into scalable, compliant, clinically ready processes.

With 30+ years of experience in viral vector development and manufacturing, we bring unmatched expertise as your trusted CDMO for AAV. From plasmids to fill/finish and advanced analytics, we provide true support, accelerating your path to the clinic.